BC007 takes out certains specific autoantibodies (the immune system attacking receptors in the body).
The whole point of BC007 is to take out these antibodies without affecting other antibodies.
That means, if Rituximab didn't work, BC007 can't possibly work. But if it does, it doesn't wipe out the rest of the immune system, like Rituximab does.
There is little point in raising 800 000 USD for this trial, as the major hurdle is selecting patients, not removing the antibodies, which can simply be done with Rituximab or even cheap steroids. Why don't we use steroids for
[...]